

IPR2023-00723
U.S. Patent 8,129,343

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00723
Patent 8,129,343

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, Patent Owner, Novo Nordisk A/S, hereby submits Mandatory Notice.

I. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1))

The real party-in-interest is Patent Owner Novo Nordisk A/S. Out of an abundance of caution, Patent Owner also identifies, as a potential real party-in-interest, exclusive licensee Novo Nordisk Inc. for purposes of providing notice. The listing of a potential real party-in-interest entity should not be deemed as an acknowledgement that, *inter alia*, any such entity actually controls this matter.

II. RELATED MATTERS (37 C.F.R. § 42.8(b)(2))

Novo Nordisk A/S identifies the following judicial and administrative matters that concern or concerned U.S. Patent No. 8,129,343.

- *Novo Nordisk Inc., et al. v. Viatris Inc.*, C.A. 23-13 (TSK) (N.D. W. Va.)
- *Novo Nordisk Inc., et al. v. Viatris Inc.*, C.A. 23-101 (CFC) (D. Del.)
- *Novo Nordisk Inc., et al. v. Mylan Pharmaceuticals Inc.*, C.A. 22-23 (IMK) (N.D. W. Va.) transferred to D. Del. as 22-1040 (CFC)
- *Novo Nordisk Inc. et al. v. Mylan Pharmaceuticals Inc.*, C.A. 22-1040 (CFC) (D. Del.)
- *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-3038 (CFC) (D. Del.)

- *Novo Nordisk Inc. et al. v. Rio Biopharmaceuticals, Inc. et al.*, C.A. 22-294
(CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Aurobindo Pharma USA, Inc. et al.*, C.A. 22-295
(CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Sun Pharmaceuticals Industries Ltd. et al.*, C.A.
22-296 (CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Zydus Worldwide DMCC et al.*, C.A. 22-297
(CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Dr. Reddy's Laboratories Ltd. et al.*, C.A. 22-298
(CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Alvogen, Inc.*, C.A. 22-299 (CFC) (D. Del.)

The same petitioner has also challenged a related patent (No. 8,536,122) in IPR2023-00722.

**III. LEAD AND BACK-UP COUNSEL AND SERVICE
INFORMATION UNDER §§42.8(b)(3)-(4):**

Lead: J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5832
steve.baughman@groombridgewu.com

Backup: Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP

801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5878
megan.raymond@groombridgewu.com

Novo Nordisk A/S consents to service through the counsel identified above.

Electronic service of documents must be sent to each of the listed email addresses of the counsel *and* Novo-Semaglutide-IPR@groombridgewu.com. To the extent physical documents are served on Novo Nordisk A/S, please address any such correspondence to lead counsel and back-up counsel at the following mailing address: J. Steven Baughman, Megan Raymond, GROOMBRIDGE, WU, BAUGHMAN & STONE LLP, 801 17th Street, NW, Suite 1050, Washington, DC, 20006.

Respectfully submitted,

Dated: April 6, 2023

By: /s/ Megan Raymond

J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5832
steve.baughman@groombridgewu.com

Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006

IPR2023-00723
U.S. Patent 8,129,343

P: (202)-505-5878
megan.raymond@groombridgewu.com

Attorneys for Patent Owner Novo Nordisk A/S

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.